University of Nottingham biopharma developing an antibody treatment for peripheral arterial disease in diabetic patients.
| Date | Round | Amount |
|---|---|---|
| Feb 2024 | Funding round IsomAb secured £7.5M led by Broadview Ventures to advance its peripheral arterial disease treatment toward clinical trials. | $9.4M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.